Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of chloroquine (CQ) and gold sodium thiomalate (GST), both of which are disease-modifying antirheumatic drugs (DMARDs) used in the treatment of rheumatoid arthritis and other inflammatory conditions. These drugs work through different mechanisms to suppress inflammation. Chloroquine reduces IL-1β mRNA expression and inhibits phosphorylation of mitogen-activated protein kinase (MAPK) p38, while gold sodium thiomalate inhibits IL-1β secretion by interfering with posttranslational IL-1β processing through selective inhibition of interleukin-1 converting enzyme (ICE)/caspase-1. The combination has been studied for its potential synergistic effects in reducing cytokine production and inflammation in rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chloroquine + gold sodium thiomalate.